SCHEMBL9065640

SCHEMBL9065640

Cc1ccc(CC(=O)C=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.48
RAB9A P51151 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
NPC1 O15118 2/20 0.47
HPGD P15428 4/20 0.46
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
CYP2C19 P33261 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17802304 0.83 ALDH1A1 (0.48) RAB9ANPC1HPGDTDP1KMT2A
SCHEMBL13740300 0.81 CTBP2 (0.47) CTBP2RAB9AL3MBTL1NPC1HPGD
SCHEMBL13000434 0.81 CTBP2 (0.47) CTBP2RAB9AL3MBTL1NPC1HPGD
SCHEMBL27275466 0.80 CA2 (0.43) LMNAGAA
SCHEMBL13727493 0.80 CA2 (0.58) CTBP2RAB9ANPC1KMT2AMEN1
SCHEMBL7992528 0.79 CTBP2 (0.46) CTBP2RAB9AL3MBTL1NPC1HPGD
SCHEMBL6451970 0.78 GAA (0.50) CTBP2RAB9ATDP1KMT2ASMN1; SMN2
SCHEMBL560200 0.78 TPMT (0.38)
SCHEMBL11982003 0.78 CA2 (0.35) HPGDKMT2AALDH1A1LMNAGAA
SCHEMBL11519547 0.78 NPC1 (0.48) CTBP2RAB9AL3MBTL1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 US disclosed
CN-115286575-A Quinolinone seven-eight membered ring derivative and synthesis method and application thereof 河南科技大学 2022-11-04 CN disclosed
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2020-11-12 US disclosed
US-10626129-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2020-04-21 US disclosed
US-20190270759-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2019-09-05 US disclosed
US-10364258-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2019-07-30 US disclosed
US-20190055269-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2019-02-21 US disclosed
US-20160281129-A1 LUMINESCENT SUBSTRATE FOR USE IN ARTIFICIAL BIOLUMINESCENT ENZYME NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2016-09-29 US disclosed
WO-1996035829-A1 PROCESS FOR THE ELECTROCHEMICAL OXIDATION OF ARYLKETONES HOECHST CELANESE CORPORATION (US) 1996-11-14 WO disclosed
US-5567299-A Process for the electrochemical oxidation of arylketones HOECHST CELANESE CORPORATION (US) 1996-10-22 US disclosed
US-5500099-A Process for the electrochemical oxidation of arylketones HOECHST CELANESE CORPORATION (US) 1996-03-19 US disclosed
EP-0295547-B1 Composition curable by photopolymerization BASF AG (DE) 1994-06-01 EP disclosed
US-4970134-A Mixture crosslinkable by photopolymerization BASF AKTIENGESELLSCHAFT (DE) 1990-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270759-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-20160281129-A1 LUMINESCENT SUBSTRATE FOR USE IN ARTIFICIAL BIOLUMINESCENT ENZYME GALC, GUSB, GLB1 CTBP2 3410/4885RAB9A 3299/4885L3MBTL1 126/4885
US-20190055269-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-10626129-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885
US-10364258-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CTBP2 3668/4885RAB9A 1820/4885L3MBTL1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.